Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02772822
Recruitment Status : Unknown
Verified May 2016 by Sinocelltech Ltd..
Recruitment status was:  Not yet recruiting
First Posted : May 16, 2016
Last Update Posted : May 16, 2016
Sponsor:
Information provided by (Responsible Party):
Sinocelltech Ltd.

Brief Summary:

The primary objective of the study is to assess the efficiency of SCT400 plus CHOP versus Rituximab plus CHOP in untreated CD20-positive DLBCL Patients.

The secondary objective of the study is to evaluate the safety of SCT400 plus CHOP, as well as the presence of human anti-chimeric antibodies (HACA).


Condition or disease Intervention/treatment Phase
Diffuse Large B Cell Lymphoma Drug: SCT400 plus CHOP Drug: Rituximab plus CHOP Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients
Study Start Date : June 2016
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Experimental: Experimental
SCT400 plus CHOP, six cycles SCT400: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
Drug: SCT400 plus CHOP
Active Comparator: Active Comparator
Rituximab plus CHOP, six cycles Rituximab: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
Drug: Rituximab plus CHOP



Primary Outcome Measures :
  1. Overall response rate(ORR) after completion of treatment [ Time Frame: 18 weeks ]

Secondary Outcome Measures :
  1. Complete remission(CR) plus complete remission/unconfirmed(CRu) after completion of treatment [ Time Frame: 18 weeks ]
  2. Progression-free survival(PFS) [ Time Frame: 1 year ]
  3. Event-free survival(EFS) at 1 year and directly after an event, whichever comes first. The events are defined as progressive disease, relapse, death from any cause, or new anticancer treatment [ Time Frame: 1 year ]
  4. Duration of remission(DOR) measured from prior achievement of complete remission or partial remission to occurrence of an event or at 1 year, whichever comes first. The events are defined as progressive disease, relapse of death from any cause [ Time Frame: 1 year ]
  5. Overall survival(OS) [ Time Frame: 1 year ]
  6. Comparison of adverse events(AEs) between the two study arms [ Time Frame: 1 year ]
  7. Number of participants with seropositive for human anti-chimeric antibody(HACA) between the two study arms [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Untreated CD20-positive DLBCL confirmed by local histopathology.
  2. International Prognostic Index (IPI) score of 0 to 2:

    Score 0 needs to accompanied by bulky disease, which is defined as the presence of a tumor mass with a diameter of more than 7.5 cm.

  3. 18 years to 70 years; Male or female patients.
  4. More than 6 months life expectancy.
  5. At least one measurable lymph node:

    For nodal tumor mass, more than 1.5 cm in the long axis and more than 1.0 cm in the short axis; For extranodal tumor mass, more than 1.0 cm in the long axis.

  6. Eastern Cooperative Oncology Group(ECOG) performance status of 0 to 2.
  7. Adequate cardiac function (LVEF≥50%).
  8. Adequate hematological function: absolute neutrophil count(ANC) ≥1.5*109/L and platelet count(PLT) ≥75*109/L.
  9. Fertile patients must use effective contraception during the treatment and within 3 months after the treatment.
  10. Signed an informed consent form which was approved by the institutional review board of the respective medical center.

Exclusion Criteria:

  1. Known allergic reactions against human or murine monoclonal antibody, murine products, or foreign proteins.
  2. Known allergic reactions against any component of CHOP regimen.
  3. Previous treatment for DLBCL, including chemotherapy, immunotherapy, partial radiotherapy for lymphoma, monoclonal antibody therapy or surgical treatment (excluding lymph node biopsies and surgical resection for non-lymphoma lesions).
  4. History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for other disease (e.g., rheumatoid arthritis), or prior use of any monoclonal antibody within 3 months.
  5. Primary central nervous system(CNS) lymphoma, secondary CNS involvement, grey zone lymphoma (GZL) between burkitt and DLBCL, primary effusion lymphoma, plasmablastic lymphoma, primary cutaneous DLBCL, anaplastic lymphoma kinase(ALK) positive DLBCL or transformed lymphoma.
  6. History of other cancer within the past 5 years except cured basal cell skin cancer, squamous cell carcinoma, cutaneous melanoma or carcinoma in situ of the cervix.
  7. Patients who have significant cardiac disease, including heart disease of grade Ⅲ of Ⅳ according to the New York Heart Association(NYHA) system, or occurrence of myocardial infarction, unstable arrhythmia, unstable angina or severe hypertension in the past 6 months or peripheral nervous system(PNS) or CNS disease.
  8. Previously suffered from progressive multifocal leukoencephalopathy.
  9. Having continuous treatment of corticosteroid drugs lasting for more than 10 days:

    Prednisone with the dosage over 30mg/day; Other corticosteroid drugs with equal dosage.

  10. Participation in another clinical trial in the past 3 months.
  11. Recent major surgery within 4 weeks.
  12. Use of hemopoietic cytokine in the past 2 weeks, e.g. granulocyte colony stimulating factor(G-CSF).
  13. Vaccination with a attenuated live vaccine within 4 weeks.
  14. Abnormal laboratory values:

    Creatinine more than 1.5 times normal value; Aspartate aminotransferase(AST) or alanine aminotransferase(ALT) more than 2.5 times normal value (5 times if hepatic involvement); total bilirubin(T-BIT) more than 1.5 times normal value(3 times if hepatic involvement); Without anticoagulant therapy, partial thromboplastin time(PTT), activated partial thromboplastin time(APTT) or international normalized ratio(INR) more than 1.5 times normal value.

  15. Active Infectious disease or significant infections requiring intravenous antibiotic therapy or hospitalization in the past 4 weeks (exception of tumor induced fever).
  16. Suspected active or latent tuberculosis.
  17. Seropositive for human immunodeficiency virus (HIV) or hepatitis C antibodies. Hepatitis B virus(HBV) positive patient (including positive hepatitis B surface antigen or positive hepatitis B virus core antibody) may participate if his serum HBV DNA level is sufficient low.
  18. Other disease or symptom by the investigator's discretion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02772822


Locations
Layout table for location information
China, Beijing
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing, China, 100076
Sponsors and Collaborators
Sinocelltech Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Yuan kai Shi, PhD Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing, China
Layout table for additonal information
Responsible Party: Sinocelltech Ltd.
ClinicalTrials.gov Identifier: NCT02772822    
Other Study ID Numbers: SCT400NHL3
First Posted: May 16, 2016    Key Record Dates
Last Update Posted: May 16, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Large B-Cell, Diffuse
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents